2seventy bio, Inc. (NASDAQ:TSVT) Director Marcela V. Maus Sells 3,900 Shares

2seventy bio, Inc. (NASDAQ:TSVT) Director Marcela V. Maus sold 3,900 shares of the firm’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $3.38, for a total transaction of $13,182.00. Following the transaction, the director now directly owns 23,752 shares of the company’s stock, valued at $80,281.76. This represents a 14.10 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

2seventy bio Stock Performance

2seventy bio stock opened at $3.23 on Friday. The company’s fifty day moving average price is $4.64 and its 200 day moving average price is $4.46. 2seventy bio, Inc. has a 1 year low of $1.67 and a 1 year high of $6.40. The stock has a market capitalization of $166.64 million, a P/E ratio of -1.69 and a beta of 1.78.

Institutional Investors Weigh In On 2seventy bio

A number of institutional investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC grew its stake in 2seventy bio by 1.1% in the 3rd quarter. Geode Capital Management LLC now owns 1,176,244 shares of the company’s stock valued at $5,553,000 after acquiring an additional 13,144 shares during the period. XTX Topco Ltd boosted its stake in 2seventy bio by 61.1% during the 3rd quarter. XTX Topco Ltd now owns 24,416 shares of the company’s stock worth $115,000 after purchasing an additional 9,257 shares during the last quarter. Wellington Management Group LLP boosted its stake in 2seventy bio by 9.0% during the 3rd quarter. Wellington Management Group LLP now owns 262,040 shares of the company’s stock worth $1,237,000 after purchasing an additional 21,673 shares during the last quarter. Western Standard LLC acquired a new stake in 2seventy bio during the 3rd quarter worth $1,350,000. Finally, State Street Corp raised its holdings in shares of 2seventy bio by 1.5% during the 3rd quarter. State Street Corp now owns 1,058,773 shares of the company’s stock worth $4,997,000 after acquiring an additional 15,638 shares during the period. Institutional investors and hedge funds own 93.90% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley dropped their price objective on shares of 2seventy bio from $7.00 to $6.00 and set an “equal weight” rating on the stock in a research note on Monday, July 29th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $9.00.

About 2seventy bio

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.